Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer

Gao, Ke; Li, Xiaoshun; Ni, Jianxin; Wu, Bing; Guo, Jing; Zhang, Rui; Wu, Guojun

doi:10.1016/j.canlet.2023.216247

Cited by 13 publications

(4 citation statements)

References 181 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the use of nanomaterials in conjunction with circRNA enhance the sensitivity of tumor cells to treatment ( Ghorbani et al, 2023 ; Su et al, 2023 ; Wang et al, 2023 ; Xie et al, 2023 ; Zetrini et al, 2023 ; Zhou et al, 2023 ). However, currently the efficacy for recurrent, drug-resistant, and metastatic prostate cancer is limited ( Antonarakis et al, 2010 ; Gao et al, 2023 ; Guo et al, 2023 ; Sooi et al, 2023 ; Su et al, 2023 ). Therefore, it is imperative to investigate the etiology, pathogenesis, and explore new treatment methods for prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Causal relationship between immune cells and prostate cancer: a Mendelian randomization study

Ye,

Deng,

Zhang

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Introduction:Despite the abundance of research indicating the participation of immune cells in prostate cancer development, establishing a definitive cause-and-effect relationship has proven to be a difficult undertaking.Methods:This study employs Mendelian randomization (MR), leveraging genetic variables related to immune cells from publicly available genome-wide association studies (GWAS), to investigate this association. The primary analytical method used in this study is inverse variance weighting (IVW) analysis. Comprehensive sensitivity analyses were conducted to assess the heterogeneity and horizontal pleiotropy of the results.Results:The study identifies four immune cell traits as causally contributing to prostate cancer risk, including CD127- CD8+ T cell %CD8+ T cell (OR = 1.0042, 95%CI:1.0011–1.0073, p = 0.0077), CD45RA on CD39+ resting CD4 regulatory T cell (OR = 1.0029, 95%CI:1.0008–1.0050, p = 0.0065), CD62L− Dendritic Cell Absolute Count (OR = 1.0016; 95%CI:1.0005–1.0026; p = 0.0039), CX3CR1 on CD14+ CD16− monocyte (OR = 1.0024, 95%CI:1.0007–1.0040, p = 0.0060). Additionally, two immune cell traits are identified as causally protective factors: CD4 on monocyte (OR = 0.9975, 95%CI:0.9958–0.9992, p = 0.0047), FSC-A on plasmacytoid Dendritic Cell (OR = 0.9983, 95%CI:0.9970–0.9995, p = 0.0070). Sensitivity analyses indicated no horizontal pleiotropy.Discussion:Our MR study provide evidence for a causal relationship between immune cells and prostate cancer, holding implications for clinical diagnosis and treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Causal relationship between immune cells and prostate cancer: a Mendelian randomization study

Ye,

Deng,

Zhang

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…This modulation is instrumental in the progression of PCa from localized to metastatic disease [20]. In the context of CRPC, miRNAs are increasingly recognized as vital epigenetic regulators and promising biomarkers [21], opening up new possibilities for therapeutic interventions [22]. Notably, miR-30c-1-3p and miR-103a-2-5p, downregulated in CRPC, function as tumor suppressors [23].…”

Section: Introductionmentioning

confidence: 99%

Trillin-Mediated Inhibition of NF-κB/COX-2 Signaling Pathways through Upregulation of miR-145-5p Targeting MAP3K11 in Castration-Resistant Prostate Cancer

Wang,

Peng,

Hao

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Prostate cancer remains a leading cause of cancer-related deaths among men worldwide, driving the need for innovative therapeutic avenues. Despite preliminary evidence supporting the anti-cancer potential of the natural compound Trillin, its effectiveness against castration-resistant prostate cancer (CRPC) has yet to be fully explored. Methods This study evaluated the anti-cancer efficacy of Trillin in CRPC cell lines DU145 and PC3 through a comprehensive set of in vitro and in vivo experiments. Assessments included cell proliferation, migration, invasion, apoptosis, and cell cycle analyses, alongside Western blot, qRT-PCR, confocal immunofluorescence, and dual luciferase assays to elucidate the molecular mechanisms underlying Trillin's action. Additionally, an in vivo CRPC xenograft model in NYG immunodeficient mice was used to assess therapeutic efficacy and toxicity. Results Trillin treatment significantly reduced CRPC cell viability, proliferation, migration, and invasion, while inducing apoptosis and cell cycle arrest at the G0/G1 phase. Mechanistically, Trillin downregulated key proteins involved in the NF-κB/COX-2 pathway, inhibited nuclear translocation of NF-κB subunits, and decreased COX-2 promoter activity. It also upregulated miR-145-5p, targeting MAP3K11, which is implicated in CRPC progression. In vivo, Trillin markedly suppressed tumor growth without observable toxicity, highlighting its potential as a therapeutic agent. Conclusion Our findings demonstrate that Trillin significantly inhibits the growth and metastatic capabilities of CRPC cells, both in vitro and in vivo, through induction of apoptosis, cell cycle arrest, and suppression of the NF-κB/COX-2 signaling pathway. By modulating miR-145-5p and targeting MAP3K11, Trillin presents a promising therapeutic strategy for CRPC, warranting further clinical investigation.

show abstract

“…An expanding body of research has underscored the significance of non-coding RNAs, encompassing microRNAs and lncRNAs, in modulating the anti-cancer and anti-diabetic effects attributed to berberine ( Ayati et al, 2017 ; Chang, 2017 ). Circular RNAs (circRNAs), as a novel class of endogenous non-coding RNA, play pivotal roles as regulators of various cellular processes ( Chen & Shan, 2021 ; Li et al, 2022 ; Meng et al, 2023 ; Mugoni et al, 2022 ; Cai et al, 2023 ; Liao et al, 2023 ; Xia et al, 2021 ; Lin et al, 2023 ; Zhou et al, 2021 ; Gao et al, 2023 ). The circRNA-miRNA-mRNA network represents a novel regulatory mechanism facilitating the effective treatment of diverse diseases using traditional Chinese medicine ( Zhang et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Berberine protects hepatocyte from hypoxia/reoxygenation-induced injury through inhibiting circDNTTIP2

Zhu,

Li,

Zhang

et al. 2023

PeerJ

View full text Add to dashboard Cite

Background During hepatic ischemia-reperfusion injury, the excessive release of inflammatory cytokines can activate the intracellular signal transduction cascade to induce hepatocyte injury. Apoptosis is an important way of cell death after I/R injury. Berberine, a common quaternary ammonium alkaloid, has anti-inflammatory, anti-oxidative stress, and anti-apoptotic effects. An increasing number of studies have revealed the importance of non-coding RNAs, including microRNA, long non-coding RNAs and circular RNAs (circRNAs), as regulators of the effects of berberine. Purpose In this study, we investigated the mechanism of berberine against liver ischemia-reperfusion injury in vitro. Study Design and Methods In this study, hypoxia-reoxygenation (H/R)-treated L02 cells were pretreated with berberine to study the role and mechanism of berberine in resisting hepatic ischemia-reperfusion injury. Results The results show that berberine pre-treatment increased the cell viability of H/R-challenged cells, reduced H/R-induced apoptosis and ROS production, reversed H/R-increased on IL-6, IL-1β, TNF-α, and H/R-decreased IL-10 expression. Mechanically, berberine protect hepatocyte from H/R injury, at least partially, through circDNTTIP2. In addition, circDNTTIP2 can bind to the TATA box of caspase3 promoter, thereby promoting caspase 3-related cell apoptosis and the release of inflammatory cytokines. Conclusion This study found that berberine has a protective effect on H/R-induced hepatocyte damage by inhibiting a novel circRNA, circDNTTIP2. This study provides potential treatment strategies and treatment targets for liver ischemia-reperfusion injury.

show abstract

Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer

Cited by 13 publications

References 181 publications

Causal relationship between immune cells and prostate cancer: a Mendelian randomization study

Causal relationship between immune cells and prostate cancer: a Mendelian randomization study

Trillin-Mediated Inhibition of NF-κB/COX-2 Signaling Pathways through Upregulation of miR-145-5p Targeting MAP3K11 in Castration-Resistant Prostate Cancer

Berberine protects hepatocyte from hypoxia/reoxygenation-induced injury through inhibiting circDNTTIP2

Contact Info

Product

Resources

About